PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) is a candidate for growth investors. Here's why.

In this article we will dive into PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) as a possible candidate for growth investing. Investors should always do their own research, but we noticed PROTAGONIST THERAPEUTICS INC showing up in our Louis Navellier growth screen, which makes it worth to investigate a bit more.

What matters for growth investors.

• The Return on Equity(ROE) of PROTAGONIST THERAPEUTICS INC is 40.75%, which is a strong number. This indicates the company's ability to generate favorable returns for shareholders and reflects its effective management of resources.
• With a track record of beating EPS estimates in the last 4 quarters, PROTAGONIST THERAPEUTICS INC showcases its consistent ability to deliver earnings surprises. This reflects the company's strong execution and its competitive position in the market.
• PROTAGONIST THERAPEUTICS INC has demonstrated strong 1-year revenue growth of 624.0%, reflecting revenue momentum and its ability to generate consistent top-line expansion. This growth underscores the company's strong market position and its potential for future success.
• PROTAGONIST THERAPEUTICS INC has achieved 184.0% growth in its revenue over the previous quarter, signaling positive momentum in its financial performance and potential market opportunities.
• The operating margin of PROTAGONIST THERAPEUTICS INC has seen steady growth over the past year, signaling improved profitability. This trend indicates the company's effective cost management and its ability to generate higher returns.
• The free cash flow (FCF) of PROTAGONIST THERAPEUTICS INC has seen steady growth over the past year, indicating enhanced cash flow generation and financial health. This trend underscores the company's effective capital management and its ability to generate sustainable cash flows.
• In the most recent financial report, PROTAGONIST THERAPEUTICS INC reported a 350.0% increase in quarterly earnings compared to the previous quarter. This notable growth indicates positive momentum in the company's financials, suggesting an upward trend
• Over the past 3 months, analysts have adjusted their EPS Estimate for PROTAGONIST THERAPEUTICS INC with a 253.0% change. This highlights the evolving outlook on the company's EPS potential.
• The recent financial report of PROTAGONIST THERAPEUTICS INC demonstrates a 350.0% increase in quarterly earnings compared to the previous quarter. This growth indicates positive momentum in the company's financials and suggests a promising upward trend
• accelerating EPS growth for PROTAGONIST THERAPEUTICS INC: the current Q2Q growth of 350.0% exceeds the previous year Q2Q growth of 164.0%.

Zooming in on the fundamentals.

ChartMill assigns a Fundamental Rating to every stock. This score ranges from 0 to 10 and is updated daily. The score is determined by evaluating multiple fundamental indicators and properties.

We assign a fundamental rating of 6 out of 10 to PTGX. PTGX was compared to 571 industry peers in the Biotechnology industry. While PTGX has a great health rating, its profitability is only average at the moment. PTGX is not valued too expensively and it also shows a decent growth rate.

Check the latest full fundamental report of PTGX for a complete fundamental analysis.

Our Lois Navellier screen will find you more ideas suited for growth investing.

Keep in mind

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.